Microcap Tokai has had a summer to forget, but its woes got worse this week as it announced that it will stop enrollment in one trial and ax another as its…

Perceptive Advisors has co-led a $14 million Series C financing to get startup Vyome into clinical testing with its lead candidate to treat antibiotic-…

Partners Eli Lilly and AstraZeneca got a leap ahead in the BACE inhibitor race as they secure a fast-track designation from the FDA for Phase III candidate…

The privately owned Dublin, Ireland-based DS Biopharma has spun out a company from its ranks in order for it to focus specifically on scarring diseases, while…

Move over Sanofi, your original $9.3 billion bid and even your second, sweetened offer has been blown out of the water by the $14 billion being put on the…

A biotech borne out of a JV between Bayer’s new research deals arm and CRISPR Therapeutics will start operations at life sciences hub Kendall Square in…

Microcap Cerulean Pharma is to cut 48% of its workforce as it reels from this week’s failed Phase II combo study with its lead candidate CRLX101.

Nordic Nanovector has completed enrollment of the first cohorts of the pre-dosed arms of its non-Hodgkin lymphoma trial.